diabetes

FDA Adds New Warning for Ileus to Ozempic Label
FDA Adds New Warning for Ileus to Ozempic Label
HCP Live
Novo Nordisk
Ozempic
diabetes
weight losss
FDA
ileus
labeling
Flag link:
Why a hidden message in Ozempic’s logo represents a big shift in drug branding
Why a hidden message in Ozempic’s logo represents a big shift in drug branding
Fast Company
Novo Nordisk
Ozempic
logo
branding
diabetes
weight loss
Flag link:
FDA panel votes against diabetes implant due to safety concerns
FDA panel votes against diabetes implant due to safety concerns
Reuters
Intarcia
diabetes
FDA
ITCA 650
Medtech
Flag link:
Intarcia, a failed diabetes "unicorn," could be resurrected
Intarcia, a failed diabetes "unicorn," could be resurrected
Axios
Intarcia
FDA
diabetes
Flag link:
Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug
Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug
CNBC
Eli Lilly
legal
Mounjaro
diabetes
Flag link:
Novo Nordisk taps Aspen to help produce insulin for Africa
Novo Nordisk taps Aspen to help produce insulin for Africa
Fierce Pharma
Novo Nordisk
diabetes
Africa
insulin
Aspen Pharmacare
drug manufacturing
Flag link:
How Payers Are Reacting to Insulin Price Changes
How Payers Are Reacting to Insulin Price Changes
Drug Channels
payers
insurance
insulin
diabetes
drug pricing
Inflation Reduction Act
Medicare
Flag link:
NICE changes its mind on Lilly's Mounjaro for diabetes
NICE changes its mind on Lilly's Mounjaro for diabetes
Pharmaphorum
Eli Lilly
Mounjaro
diabetes
NHS
UK
Flag link:
Novo Nordisk Is Already Working on Ozempic 2.0
Novo Nordisk Is Already Working on Ozempic 2.0
Motley Fool
Novo Nordisk
diabetes
obesity
weight loss
Ozempic
Wegovy
Flag link:
Abbott and Bigfoot Take Relationship to the Next Level
Abbott and Bigfoot Take Relationship to the Next Level
Medical Devices and Diagnostics Industry
Abbott Labs
Bigfoot Biomedical
M&A
Medtech
diabetes
Flag link:
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
Flag link:
US senators push drugmakers for details on low-cost insulin programs
US senators push drugmakers for details on low-cost insulin programs
Yahoo/Reuters
Senate
insulin
drug pricing
Novo Nordisk
Eli Lilly
Sanofi
diabetes
Flag link:
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Motley Fool
Novo Nordisk
Ozempic
diabetes
weight loss
liver disease
addiction
cardiovascular disease
Flag link:
Medtronic pleased with Diabetes progress as new CGM’s FDA review ‘is progressing’
Medtronic pleased with Diabetes progress as new CGM’s FDA review ‘is progressing’
Mass Device
Medtronic
Medtech
diabetes
FDA
continuous glucose monitoring
MiniMed 780G
Flag link:
Amazon Pharmacy rolls out insulin discount coupons
Amazon Pharmacy rolls out insulin discount coupons
Pharmaphorum
Amazon
Amazon pharmacy
insulin
discount coupons
diabetes
Flag link:
Lilly's $13.5M insulin pricing settlement gets pushback from 9 states
Lilly's $13.5M insulin pricing settlement gets pushback from 9 states
Fierce Pharma
Eli Lilly
drug pricing
insulin
Humalog
legal
diabetes
Flag link:
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2
Fierce Pharma
Novo Nordisk
Eli Lilly
obesity
diabetes
earnings
Flag link:
TheracosBio reports data from trial of diabetes therapy
TheracosBio reports data from trial of diabetes therapy
Clinical Trials Arena
TheracosBio
diabetes
type 2 diabetes
Brenzavvy
clinical trials
Flag link:
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Ozempic Could Have a New Multibillion-Dollar Market Opportunity. Is Novo Nordisk Stock a No-Brainer Buy?
Motley Fool
Ozempic
Novo Nordisk
weight loss
diabetes
Flag link:
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
Fierce Pharma
Boehringer Ingelheim
Jardiance
diabetes
earnings
Flag link:

Pages